From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

ABSTRACT: Survival of myeloma patients has greatly improved with the use of autologous stem cell transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. Compared to bortezomib- and lenalidomide-based regimens alone, the addition of high-dose melphalan followed by autologous transplantation significantly improves progression-free survival, although an overall survival benefit was not observed in all trials. Moreover, follow up of recent trials is still too short to show any difference in survival. In the light of these findings, novel agent-based induction followed by autologous transplantation is considered the standard upfront treatment for eligible patients (level of evidence: 1A). Post-transplant consolidation and maintenance treatment ca

SUBMITTER: Gay F 

PROVIDER: S-EPMC5792264 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature